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ABSTRACT 
Objective: The aim of this work is the assessment of an eventual improvement in flowability of free flowing excipients on formulations containing 
Noveon AA1 and their influence on compactibility and release profile.  
Methods: Mixtures containing 20% Noveon AA1 and variable proportions of metronidazole and the free flowing excipients Prosolv EasyTab and 
GalenIQ 720 and 721were tested in their powder flow rate and the tablets compactibility and released profiles.  
Results: The powder flowability obtained with GalenIQ is about 20% better than that obtained with EasyTab. However, it is lesser than that 
considered as acceptable for a high-speed tableting machine. EasyTab reduces the drug release up to a half along with a continuing flattening of the 
release profile. This is attributed to an increasing tortuosity of the drug release path as the proportion EasyTab increases. GalenIQ restricts drug 
release in about a third with a lesser change in the release mechanism. This is attributed to competition for the available water inside the tablet, 
between the hydrating Noveon AA1 and the dissolving GalenIQ. The compactibility of the metronidazole/Noveon AA1 mixtures increases after 
addition of EasyTab in about 3.5 N per unit percentage of the added excipient while GalenIQ does it in about 2.6 N.  
Conclusion: The powder flowability of mixtures of metronidazole with Noveon AA1 was not suited for direct compression after addition of 40% of 
the free-flow excipient. The free-flow excipients reduce the metronidazole release rate and increase its compactibility. It was not observed a 
different clear functioning between both types of GalenIQ.  
Keywords: Compactibility profiles, Powder flowability, Dissolution profiles, excipient functionality, Metronidazole, Controlled release, Noveon AA1, 
GalenIQ, EasyTab 




Physical and technological characterization of drugs and 
pharmaceutical excipients is a requirement that provides data that 
can be predictive in nature regarding the performance of final 
dosage forms. Manufacturers generally provide some physical 
testing data, such as particle size, surface area, density or porosity 
[1]. Additionally, other technological tests may not be reported such 
a
Noveon AA1 is an acrylic acid polymer with application to solid 
dosage formulations as a controlled release polymer. Noveon AA-1 
has binding properties that provide helpful mechanical properties of 
tablet formulations, improved tablet hardness and decreased tablet 
friability. Nevertheless, its hygroscopicity demands processing with 
low relative humidity. It does not show a free-flowing behavior. 
Noveon AA1 has a very fine particle size and static loads. Further, 
segregation can occur in powder blend [2]. 
s powder flowability, tabletability and performance in dissolution. 
These data provide insight into how a particular material will 
behave in a given process or final dosage form. 
Noveon AA1 has been regarded as a matrix for controlled release, 
displaying enhancing properties of the overall controlled release 
performance of HPMC. Noveon AA1 also improves the 
compactibility, however, decreases the flowability [3]. 
Microcrystalline cellulose reduces the effect of Noveon AA1 to 
decrease the flowability of powder blends while dicalcium 
phosphate dihydrate increases importantly the flowability of blends 
containing Noveon AA1 [4]. 
The poor flowability is the main drawback that characterizes 
Noveon AA1. It displays a Carr’s index (CI) or compressibility index 
of 39%, which stands for a cohesive or extremely cohesive powder 
[5]. Noveon AA1 is considered dysfunctional in this respect. 
Microcrystalline cellulose type 102 (CI=21.7%) is considered at the 
limit for powders that can be processed in a high-speed tableting 
machine. The compressibility index of other excipients such as 
GalenIQ 720 (CI=13.8%), display values indicating a good powder 
flowability [6]. 
Direct compression is the simplest means of production of tablets 
dosage forms. It takes a blending of the drug with the appropriate 
excipients before the compression. Whereby the minimum number 
of excipients is mostly desired. Tablet development for oral delivery 
of drugs is accomplished by the availability and use of suitable 
excipients with multifunctionalities [7]. 
Aerosil is one of the most used compounds for flow regulation in 
pharmaceutical applications [8]. Aerosil has been employed to 
prevent obstruction of the flow of hygroscopic powders. Sennoside 
binary mixtures with microcrystalline cellulose showed an increased 
powder flow rate when added of 4% Aerosil [9]. The addition of 
Aerosil to mixtures of metronidazole with Noveon AA1 reduces the 
compressibility index; a proportion of 4% seems to be at the limit of 
improvement of powder flowability of that formulation [5].  
Physical modification and/or co-processing of excipients have 
accomplished the purpose of direct compression excipients with the 
implementation of powder and tableting requirements. Various 
types of excipients involving physical modification and/or co-
processing are currently in pharmaceutical applications. These 
products are commonly designed as free flowing excipients and 
maintain the powder velocity once it is in motion. These excipients 
show superior flow properties, mostly due to controlled particle 
form, particle size and particle size distribution. 
GalenIQ 720 is a form of spherical agglomerated isomalt used for 
direct tableting and for filling capsules. Chemically, it is disaccharide 
alcohol in a 1:1 ratio of 6-O-D-glucopyranosyl-D-sorbitol and 1-O-D-
glucopyranosyl-D-mannitol dihydrate (GSP/GMP). It is found in 
pharmacopeias as isomalt. Due to its properties as its taste and low-
calorie content, as well as its low hygroscopicity offers advantages 
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over other polyols when formulated into pharmaceutical products. 
Particularly, it is used as an excipient in tablets [10-11]. 
A comparable product produced from a basic isomalt product with a 
GSP/GMP ratio of 3:1 is GalenIQ 721. The main difference between 
the two agglomerated products is their water solubility. Both 
agglomerated isomalt types with a mean particle size of about 240 
µm have an excellent flowability, as reflected by a low Hausner ratio 
(1.14) and free flow through the smallest orifice (2.5 mm). Both 
agglomerated isomalt types display an improved lubricant 
sensitivity and good compaction properties [12].  
GalenIQ 720 shows a particle size distribution with a d50%
The compactibility of GalenIQ 720 (134 N) is roughly 37% of that of 
microcrystalline cellulose (357 N). However, GalenIQ 720 exhibits 
an increased compactibility in mixtures with a lubricant, against the 
known fall of compactibility of microcrystalline cellulose [13-15]. 
 of 200 µm 
that is 10% higher than that of GalenIQ 721 (180 µm). Its solubility 
(25 g/100 ml water) is lower than that of GalenIQ 721 (42 g/100 g 
water) [13].  
The powder flow rate of GalenIQ 721 is approximately 63% larger 
than that of microcrystalline cellulose type 102 while its 
compactibility is about two-thirds lesser of that shown by similar 
tablets [16]. The excellent flow properties of GalenIQ 720 and 721 
are attributed to favorable particle form and size distribution [17]. 
A co-processed excipient called Prosolv EasyTab acts as a binder, 
disintegrant, lubricant and a glidant. Its main recommended 
application is ready to use excipient composite. Prosolv EasyTab is a 
homogenous lubricant-coated high functionality excipient 
composite. It is composed of four individual components: a binder-
filler (microcrystalline cellulose-96.50%), a glidant (colloidal silicon 
dioxide-2.00%), a super disintegrant (sodium starch glycolate-
1.00%), and a lubricant (sodium stearyl fumarate-0.50%). These 
components maintain their chemical identities while synergistically 
providing increased functional performance [18-19]. The Prosolv 
EasyTab is particularly suitable for abrasive, bad flowing and fluffy 
actives formulations. This excipient composite shows an average 
particle size of 130 µm and an average bulk density of 0.36 g/ml [20]. 
A mixture of the drug Vardenafil hydrochloride with Prosolv 
EasyTab (5:97.5) showed a compressibility index of 14.6% and a 
tablet hardness of 5.2 kg/cm2
The aim of this work is the assessment of an eventual improvement in 
flowability of free flowing excipients on formulations containing 
Noveon AA1 and their influence on compactibility and release profiles.  
. These data stand for an efficient flow 
as well as compressibility properties [21].  
MATERIALS AND METHODS 
Materials 
The materials used in this study were Noveon AA1, obtained from 
Lubrizol; Prosolv EasyTab obtained from JRS Pharma; agglomerated 
isomalt (EP, BP, USP-NF), GalenIQ 720 and 721, from BENEO-
Palatinit GmbH, and metronidazole from Química Alkano SA de CV. 
All materials obtained from subsidiaries in Mexico. The drug and 
excipients were used as received. 
Methods 
Preparation of mixtures 
Corresponding amounts of the materials were weighed to obtain 30 
g of metronidazole mixtures with different proportions of each Free-
flow excipient (Prosolv EasyTab and GalenIQ 720 and 721): 5%, 
10%, 15%, 20%, 30%, and 40%, maintaining a constant proportion 
of 20% for Noveon AA1 in all mixtures. The powders were 
transferred to a mortar and mixed manually for 30 min.  
Assessment of the powder flow rate  
A sample of approximately 25 g is weighed, and its flow rate 
assessed, through a glass funnel with an opening of 8 mm diameter. 
The funnel is placed on a graduated cylinder of 100 ml, which is 
mounted on a tapper. The sample is gently poured into the funnel, 
whose bottom opening was blocked. While unlocked, the tapper 
starts the movement. The tapper is set at a constant speed of 60 taps 
per minute, tapping from a height of 1.5 cm. The time it takes to 
move the total powder poured through the funnel is registered. The 
flow rate is calculated by dividing the sample mass by the time. The 
assay is repeated five times, sieving the powder through a mesh 
number 20 after each measurement. The average of the five 
repetitions is taken as the flow rate. 
Dissolution test 
Tablets obtained as described in the subtitle compactibility and 
compacted at a compaction pressure of 109 MPa were used to 
determine the dissolution behavior. The dissolution profile was 
carried out for a period of six hours using a paddle apparatus at 50 
rpm. Each time three tablets were placed in 900 ml of distilled water at 
37ºC. At predetermined time intervals, samples were removed, filtered 
and evaluated with a spectrophotometer (Beckman DU 650, λ=319 
nm). After each sample was removed, the same quantity of liquid was 
replaced. The percentage of drug released was based on the total 
tablet content after dissolution in a magnetic stirring device. 
Compactibility 
Tablets weighing 150 mg were compacted for 10 s in a hydraulic 
press, at a series of compaction pressures from 27 MPa to 240 MPa, 
using 8 mm circular flat-shaped punch and die. Tablet crushing 
strength was measured in triplicate, registering the results as an 
average. For this purpose, a tablet hardness tester Erweka TBH30 
was used. The procedure involved placing each tablet diametrically 
between two flat surfaces and applying pressure until the tablet 
breaks down. 
RESULTS AND DISCUSSION 
Influence of flow agents on the flowability of metronidazole/ 
Noveon AA1 powder blends 
In bulk powder applications, maintaining a free-flow behavior 
during processing is critical in order to minimize downtime and 
ensure product quality and homogeneity. A free-flow excipient 
possesses the ability to maintain the powder velocity once it is in 
motion. In this respect, multifunctional excipients such as EasyTab, 
GalenIQ 720 and GalenIQ 721 can serve as materials preventing 
packing of particles when mass is flowing. This type of excipient are 
considered to help ensuring free-flow of powdered formulations. 
Fig. 1 depicts the effect of the above-mentioned excipients on the 
powder flow rate of metronidazole mixtures containing 20% Noveon 
AA1. The addition, of these different excipients, shows a better 
flowability of blends with GalenIQ compared to those blends with 
Prosolv EasyTab. Among the blends of the two different types of 
GalenIQ, there is no practical difference in their flowability. Although 
GalenIQ 720 displays a higher flowability at a high excipient 
proportion (equal parts of metronidazole and GalenIQ 720). GalenIQ 
is the excipient of choice with respect to flowability. 
 
 
Fig. 1: Effect of different proportions of free-flow 
excipients/metronidazole on the powder flow rate of mixtures 
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The metronidazole used here displays a high flowability (6.2 
g/s) when determined under the similar circumstances (orifice 
size and speed of the tapper). In the same way, GalenIQ 720 
displays a similar flowability (5 g/s) [6]. On the other hand, 
Noveon AA1 exhibits a high compressibility index (39%) and 
quite a slow powder flow 0.0372 g/s. It indicates an exceedingly 
poor powder flowability [5]. The results obtained currently are 
in between of those of individual components of the blends. 
Although the powder flow rate of the blends containing GalenIQ 
is better than those of EasyTab, this powder flow is still about a 
half of the powder flow rate of microcrystalline cellulose type 
102 [6].  
Although a mixture of the Vardenafil hydrochloride with Prosolv 
EasyTab (5:97.5) showed an efficient flow, it occurred at a high 
proportion of the excipient [21]. Currently, excipient proportions 
of up to 40% does not show an adequate flow improvement. In the 
same way, the excellent flow properties of GalenIQ 720 and 721 
[17] could not be confirmed when used here at proportions up to 
40%.  
Influence of flow agents on the release profile of 
metronidazole/Noveon AA1 tablets 
Oral dosages with desired optimal release characteristics to meet 
the therapeutic windows usually either contain polymers in matrices 
or coated around multi particulates. The use of polymers such as 
Noveon AA1 displays drug release mechanisms where water 
molecules tend to diffuse into these systems, causing swelling which 
results in diffusion of drug molecules out through the swollen 
polymer matrix. 
In this case, the kinetics of drug release was evaluated with the aid of 
a model based on the Weibull distribution (Eq. 1), which has been 
used for the evaluation of sigmoid release profiles from matrix 
systems. Mathematical models such as this one are normally used to 
investigate a proper “fit” for the experimental measurements of drug 
release. In this model, (% D) means the percentage drug dissolved at 
a time (t). 
 Eq. 1 
Fig. 2 depicts the release profile of metronidazole from tablets 
containing 20% Noveon AA1 and different proportions of 
metronidazole and the free-flow excipient EasyTab. The 
experimental data were treated according to the above-mentioned 
model to obtain the depicted regression lines.  
 
 
Fig. 2: Release profile of EasyTab/metronidazole tablets 
containing 15% and 40% EasyTab and 20% Noveon AA1, n=3. 
Experimental points and calculated regressions 
 
Currently, the drug release kinetics does not correspond to a zero 
order. Even if the profile up to 3-4 h could be described itself as zero 
order. The metronidazole release profile is assigned to an 
anomalous transport including mechanisms of diffusion and 
relaxation of the polymeric matrix.  
EasyTab obstructs metronidazole release. The higher obstruction 
corresponding to the higher EasyTab proportion. This behavior has 
been ascribed to the microcrystalline cellulose water insolubility 
that provides an additional barrier by increasing the tortuosity of 
the diffusion path, reducing the drug release rate. The 
microcrystalline cellulose content of EasyTab is 96.5% [22-23]. 
Table 1 summarizes the calculated regression parameters for the 
release profiles of metronidazole from tablets containing a fixed 
proportion of Noveon AA1 (20%) and varying proportions of 
metronidazole and EasyTab. As can be seen, an increasing 
proportion of EasyTab in the mixtures produces tablets with an 
increasing time to attain 50% drug dissolved. The use of increasing 
proportions of EasyTab increases the restriction degree of 
metronidazole release, prolonging the time necessary to dissolve 
50% of the drug. The t50%
Table 1: Regression parameters of release profiles of metronidazole tablets containing different proportions of EasyTab and 20% Noveon 
AA1, calculated according to equation 1 
 is in the range 115 min to 223 min, with a 
range width of 108 min. 
Easytab (%) Slope Intercept r t 2 50% (min) 
0 1.3447 -6.743 0.997 115 
5 1.4664 -7.6508 0.989 143.7 
10 1.5458 -8.2589 0.985 164.9 
15 1.2598 -6.8335 0.996 169.6 
20 1.2437 -6.9679 0.993 201.9 
30 1.3341 -7.5454 0.981 217.2 
40 1.3299 -7.5554 0.989 222.6 
Data calculated as a whole from three dissolution curves  
 
Fig. 3 depicts the by regression calculated release profiles of 
metronidazole from tablets containing different proportions of 
EasyTab and a constant proportion of Noveon AA1 (20%). These 
curves were obtained from a calculated response surface. As above-
mentioned, increasing proportions of EasyTab produce an 
increasing restriction of drug release. At the same time, the 
increasing proportions of EasyTab shift the release kinetics towards 
an order zero. The degree of curvature of the metronidazole 
dissolution profile decreases as the proportion of EasyTab increases, 
the release kinetics moving in the direction of a zero order kinetics.  
In controlled release diclofenac sodium pellets, based on isomalt, 
sugar, and microcrystalline cellulose, it was comparatively observed 
that dissolution rates for the soluble sucrose-and isomalt-based 
pellets were similar and were significantly higher compared to those 
of the microcrystalline cellulose-based pellets [24]. 
Table 2 summarizes the calculated regression parameters for the 
release profile of metronidazole tablets containing a fixed 
proportion of Noveon AA1 (20%) and different proportions of 
GalenIQ 720. GalenIQ 720 also shows a restrictive effect on the 
release of metronidazole, although in a smaller range.  
The effect of the GalenIQ 720 to restrict the release of metronidazole 




















) is in a range from 115 min to 152 min, with a wide range 
of 37 min. This wide range is approximately 35% of that produced 
by tablets containing EasyTab. 
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Table 2: Regression parameters of release profiles of metronidazole tablets containing different proportions of GalenIQ 720 and a fixed 
proportion of Noveon AA1 (20%), Data calculated according to equation 1 
GalenIQ 720 (%) Slope Intercept r t 2 50%(min) 
0 1.345 -6.743 0.997 115 
5 1.666 -8.108 0.998 104 
10 1.48 -7.333 0.997 111 
15 1.612 -8.155 0.998 125 
20 1.594 -8.082 0.987 126 
30 1.751 -9.109 0.997 147 
40 1.677 -8.794 0.992 152 
Data calculated as a whole from three dissolution curves  
 
 
Fig. 3: Release profiles of metronidazole tablets containing 
different proportions of Easy tab and 20% Noveon AA1, 
obtained from a calculated response surface 
 
The effect of GalenIQ 720 on the release profile cannot be ascribed to 
an obstruction effect or the addition of an extra barrier over the 
release path. GalenIQ 720 is water-soluble and must disappear after 
dissolution, leaving in the matrix an increased porosity and an 
increasing release rate. However, it does not happen. Instead, the 
effect of GalenIQ can be attributed to a delayed drug release. This 
delay occurred because of competition for available water inside the 
tablet. Both excipients, GalenIQ 720 and Noveon AA1 compete for 
the available water, delaying the polymer hydration and the GalenIQ 
720 dissolution. The consequence is a decreased drug release rate. 
However, the lesser release rate is partially compensated by an 
increased matrix porosity after the dissolution of GalenIQ 720. The 
result is a reduced effect on release rate. 
Competition for the available water inside a tablet has been 
observed in tablets containing a water-soluble diluent such as 
Pharmatose DCL11 and disintegrants with different hygroscopicity. 
Pharmatose DCL11 showed a less important improvement of 
norfloxacin dissolution when mixed with the high hygroscopic 
Starch 1500. The addition of Pharmatose DCL, 11 to tablets of the 
low hygroscopic PVP XL 10 and norfloxacin, showed no inhibition 
but potentiated the dissolution of norfloxacin substantially. These 
effects were attributed to competition for the available water inside 
the tablet and to different water consume, for dissolution or 
hydration, by the diluent and the disintegrants [25]. 
Fig. 4 depicts the effect of GalenIQ 720 on the by regression 
calculated release profile of metronidazole/Noveon AA1 matrices. 
As can be seen, the release profile change in a less important manner 
its degree of curvature. These matrices modify in a lesser extent the 
release mechanism caused by the addition of different proportions 
of GalenIQ 720, compared to EasyTab. However, this lesser impact on 
the release mechanism can also be ascribed to a lesser restriction of drug 
dissolution. Matrices containing 40% EasyTab require 223 min to 
dissolve 50% of the drug while matrices containing GalenIQ 720 require 
30% lesser time to dissolve the same quantity of drug, only 152 min. 
 
 
Fig. 4: Release profile of metronidazole tablets containing 
different proportions of GalenIQ 720 and 20% Noveon AA1, 
obtained from a calculated response surface 
 
Table 3 summarizes the calculated regression parameters of release 
profiles of metronidazole tablets that contain different proportions 
of GalenIQ 721. Compared with regression parameters of tablets 
containing GalenIQ 720 (table 2) these results can be considered 
similar. The release profiles are similar, despite a lesser solubility in 
water of GalenIQ 720 (25 g/100 ml water), compared to GalenIQ721 
(42 g/100 g water). 
 
Table 3: Regression parameters of release profiles of metronidazole tablets containing different proportions of GalenIQ 721 and 20% 
Noveon AA1, calculated according to equation 1 
GalenIQ 721 (%) Slope Intercept r t 2 50% (min) 
0 1.3447 -6.743 0.9973 115 
5 1.624 -7.904 0.993 103 
10 1.571 -7.863 0.994 118 
15 1.643 -8.181 0.996 116 
20 1.628 -8.214 0.998 124 
30 1.956 -9.833 0.994 126 
40 1.765 -9.325 0.991 160 
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Fig. 5 depicts the effect of different proportions of GalenIQ 721 on 
the calculated release profile of metronidazole tablets containing 
20% Noveon AA1. In spite of a different solubility of GalenIQ type 




Fig. 5: Release profiles of metronidazole tablets containing 
different proportions of GalenIQ 721 and 20% Noveon AA1, 
obtained from a calculated response surface 
 
Fig. 6 depicts the effect of different proportions of the free-flow 
excipients on the calculated time to attain 50% metronidazole release 
from tablets containing 20% Noveon AA1. This fig. shows no practical 
differences between the two types of GalenIQ and the greater restriction 
effect of EasyTab on the metronidazole release behavior. 
 
 
Fig. 6: Effect of different proportions of free-flow excipients on 
the time necessary to release 50% metronidazole from tablets 
containing 20% Noveon AA1, n=3 
Influence of free-flow excipients on compactibility of 
metronidazole/Noveon AA1 tablets 
A pharmaceutical tablet is a large group of particles held together by 
active bonds between external surfaces of particles. The compaction 
properties of pharmaceutical powders are characterized by their 
compactibility. Compactibility is defined as the ability of material to 
form coherent agglomerates after compression. It is quantified more 
frequently by a curve of tensile strength versus compression 
pressure (compactibility profile). Compactibility has been defined 
with regression parameters of equation 2 [26-27]. 
Eq. 2 
Where: D is the hardness or crushing strength of the tablets, Dmax is 
the greatest tablet hardness attained, Pc is the compaction pressure, 
n is the slope of the curve, and I is the intercept of the curve.  
As can be seen in fig. 7, the use of EasyTab allows greater 
compactibilities of Metronidazole/Noveon mixtures, followed by 
GalenIQ 721 and thereafter by GalenIQ 720. In this case, using a free-
flow excipient proportion of 20%. This fig. displays the experimental 
points and the calculated regressions with equation 2. 
 
 
Fig. 7: Effect of 20% of different free-flow excipients on the 
compactibility profile of metronidazole tablets containing 20% 
Noveon AA1, n=3. Experimental points and calculated 
regressions 
 
Table 4 summarizes the calculated regression parameters of 
compactibility profiles of metronidazole tablets containing different 
proportions of Prosolv EasyTab and a constant 20% Noveon AA1. 
Given the regression parameters, a response surface was 
constructed showing the compactibility of the mixtures with 
different proportions of EasyTab and compacted at different 
compaction pressures. Fig. 8 depicts this relationship. 
 
Table 4: Regression parameters of compactibility profiles of metronidazole tablets containing different proportions of EasyTab and 20% 
Noveon AA1, calculated according to equation 2 
Easytab (%) Slope Intercept r TH 2 136MPa (N)* 
0 0.652 -2.993 0.968 73 
5 1.416 -6.398 0.946 202 
10 1.416 -6.209 0.953 217 
15 1.480 -6.617 0.926 237 
20 1.466 4.490 0.964 258 
30 1.504 -6.771 0.917 293 
40 1.529 -6.680 0.948 323 
Data calculated as a whole from three compactibility curves.* TH = tablet hardness 
 
Fig. 8 shows an increase in tablet hardness with an increasing 
proportion of the free-flowing excipient EasyTab in the mixtures. 
The before observed properties of EasyTab as a binder [20-21] are 
confirmed with the current results. Furthermore, the effect of the 
compaction pressure is an increasing tablet hardness as the 
compaction pressure increases, leveling at certain compaction 
pressure. The latter relationship corresponds to the second part of 
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Fig. 8: Calculated response surface for compactibility of 
metronidazole tablets containing different proportions of 
EasyTab and 20% Noveon AA1 
 
Similarly, table 5 summarizes the regression parameters of 
compactibility profiles of metronidazole tablets containing different 
proportions of GalenIQ 720 and a constant proportion of Noveon 
AA1 (20%). As observed by EasyTab, it can also be observed an 
increasing tablet hardness as the proportion of the free-flow 
excipient increases. However, the improvement in compactibility is 
clearly lesser in the case of GalenIQ 720. 
Fig. 9 depicts the calculated response surface displaying the effect of 
compaction pressure and the proportion of GalenIQ 720 on 
compactibility of metronidazole/Noveon AA1 tablets. The effect of 
compaction pressure and GalenIQ 720 proportion is similar as 
observed before by EasyTab although of a different magnitude, 
lesser values of tablet hardness. 
 
 
Fig. 9: Calculated response surface for compactibility of 
metronidazole tablets containing different proportions of 
GalenIQ 720 and 20% Noveon AA1 
 
Table 6 summarizes the calculated regression parameters of 
compactibility curves of formulations containing different proportions 
of GalenIQ 721. Considering a compaction pressure of 136 MPa, tablets 
containing different proportions of GalenIQ 720 show an average 
tablet hardness of 188 N while formulations with similar proportions 
of GalenIQ 721 show an almost identical value, 189 N. 
  
Table 5: Regression parameters of compactibility profiles of metronidazole tablets containing different proportions of GalenIQ 720 and 
20% Noveon AA1, calculated according to equation 2 
GalenIQ 720 (%) Slope Intercept r T H 2 136MPa (N) 
0 0.652 -2.993 0.968 73 
5 1.614 -7.196 0.916 168 
10 1.643 -7.497 0.929 182 
15 1.706 -7.844 0.933 189 
20 1.414 -6.511 0.992 200 
30 1.827 -8.330 0.810 242 
40 2.034 -9.183 0.931 266 
 Data calculated as a whole from three compactibility curves. * TH = tablet hardness 
 
Table 6: Regression parameters of compactibility profiles of metronidazole tablets containing different proportions of GalenIQ 721 and 
20% Noveon AA1, calculated according to equation 2 
GalenIQ 721 (%) Slope Intercept r *TH 2 136MPa (N) 
0 0.652 -2.993 0.968 73 
5 1.324 -6.003 0.783 160 
10 1.572 -6.890 0.880 186 
15 1.505 -6.741 0.848 202 
20 1.534 -6.748 0.881 227 
30 1.489 -6.544 0.844 237 
40 1.548 -6.663 0.931 242 
 Data calculated as a whole from three compactibility curves.* TH = tablet hardness  
 
Fig. 10 depicts the effect of compaction pressure and the proportion 
of the free-flow excipient GalenIQ 721 on the tablet hardness of 
metronidazole tablets containing 20% Noveon AA1. The observed 
relationships are similar to those observed before by GalenIQ 720. 
Fig. 11 depicts the comparative compactibility displayed by 
formulations containing the three different free-flow excipients. 
Taking as a reference for compactibility the tablet hardness attained 
at a compaction pressure of 136 MPa, the presence of Prosolv 
EasyTab produces an increase in tablet hardness of about 3.5 N per 
unit percentage of the added excipient. On the other hand, GalenIQ 
produces an average increase of the tablet hardness of about 2.6 N 
per unit percentage of the added excipient. In this fig., the greater 
compactibility of mixtures containing 20% GalenIQ 721 over those 
containing 20% GalenIQ 720, observed before in fig. 7, is no more 
perceived. The effect of both types of GalenIQ on compactibility of 
metronidazole/Noveon AA1 tablets is similar. These results are 
consistent with those published by Bolhuis [14] and differ from 
those published by Mužíková and Pavlasová [28], who reported a 
better compressible GalenIQ720 than GalenIQ721. 
The greater agglutinant properties of EasyTab are mainly attributed 
to its high content in microcrystalline cellulose (96.5%) [20]. 
Compactibility of pure microcrystalline cellulose type 102 has been 
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observed to be 2-3 times higher than that of pure GalenIQ 720, 
decreasing the difference after dilution with the drug metronidazole 
[14]. The current results are similar showing lesser differences in 
compactibility, although all the time higher for tablets containing 
EasyTab. 
 
Fig. 10: Calculated response surface for compactibility of 
metronidazole tablets containing different proportions of 
GalenIQ 721 and 20% Noveon AA1 
 
 
Fig. 11: Effect of different proportions of free-flow excipients on 
the by regression calculated tablet hardness (Pc=136 MPa) of 
metronidazole tablets containing 20% Noveon AA1, n=3 
 
CONCLUSION 
The aim to improve the powder flowability of mixtures of 
metronidazole with Noveon AA1 was not sufficiently satisfied by the 
addition of the free-flow excipients EasyTab and GalenIQ. The 
resulting powder flow rate is lesser than a half of that of 
microcrystalline cellulose type 102, commonly taken as reference for 
the minimum acceptable. Anyway, the powder flowability obtained 
with GalenIQ is about 20% better than that obtained with EasyTab. 
The effect of the addition of the free-flow excipients on 
metronidazole release from tablets containing 20% Noveon AA1 is a 
restriction of the drug release that increases as the proportion of the 
free-flow excipient increases. EasyTab restricts the drug release up 
to a half after addition of 40% of the excipient. The EasyTab release 
restriction goes along with a continuing flattening of the release 
profile towards a zero order kinetics. This release restriction is 
mainly attributed to an increasing tortuosity of the drug release path 
as the proportion of the water-insoluble EasyTab increases. In 
addition, GalenIQ also produces an increasing restriction of drug 
release although only one third, after addition of 40% of excipient. 
The addition of GalenIQ does not display an important change in the 
release mechanism. The effect of GalenIQ on drug release restriction 
is attributed to competition for the available water inside the tablet. 
This competition occurs between the hydrating Noveon AA1 and the 
dissolving GalenIQ.  
The compactibility of the metronidazole/Noveon AA1 mixtures 
increases after addition of both free-flow excipients EasyTab and 
GalenIQ. EasyTab increases the compactibility in about 3.5 N per 
unit percentage of the added excipient while GalenIQ does it in about 
2.6 N. 
There are no clear differences in the functioning of the powders 
compactibility, the rate of drug release or the powder flowability 
between the two types of GalenIQ.  
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